These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34694788)

  • 41. Negative values and variance functions: Implications for statistical analysis.
    Sadler WA
    Ann Clin Biochem; 2021 Sep; 58(5):395-399. PubMed ID: 33334133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Accurate Substitution Method To Minimize Left Censoring Bias in Serum Steroid Measurements.
    Handelsman DJ; Ly LP
    Endocrinology; 2019 Oct; 160(10):2395-2400. PubMed ID: 31199478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testing for differences in changes in the presence of censoring: parametric and non-parametric methods.
    Wu MC; Hunsberger S; Zucker D
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):635-46. PubMed ID: 8023039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lag-censoring analysis: lights and shades.
    Tripepi G; Heinze G; Jager KJ; Stel VS; Dekker FW; Zoccali C
    Nephrol Dial Transplant; 2015 May; 30(5):700-5. PubMed ID: 25883199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer.
    Bagust A; Beale SJ
    Med Decis Making; 2018 Oct; 38(7):789-796. PubMed ID: 30125510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Research considerations: power analysis and effect size.
    Connelly LM
    Medsurg Nurs; 2008 Feb; 17(1):41-2. PubMed ID: 18429540
    [No Abstract]   [Full Text] [Related]  

  • 47. How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?
    McNamee R
    Stat Med; 2017 Sep; 36(21):3315-3333. PubMed ID: 28621000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Causal inference in tuberculosis treatment studies: bias considerations and data needs.
    Franke MF; Rodriguez CA; Mitnick CD
    Int J Tuberc Lung Dis; 2019 Aug; 23(8):960-961. PubMed ID: 31533889
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluating ethnography: considerations for analysis.
    Mackenzie AE
    J Adv Nurs; 1994 Apr; 19(4):774-81. PubMed ID: 8021400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selection bias in epidemiologic studies.
    Kleinbaum DG; Morgenstern H; Kupper LL
    Am J Epidemiol; 1981 Apr; 113(4):452-63. PubMed ID: 6971055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regression analysis of grouped survival data: informative censoring and double sampling.
    Baker SG; Wax Y; Patterson BH
    Biometrics; 1993 Jun; 49(2):379-89. PubMed ID: 8369374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Statistical Treatments of Left-Censored Environmental Data Using Coincident Uncensored Data Sets. II. Group Comparisons.
    Antweiler RC
    Environ Sci Technol; 2015 Nov; 49(22):13439-46. PubMed ID: 26490190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simulating survival data with predefined censoring rates for proportional hazards models.
    Wan F
    Stat Med; 2017 Feb; 36(5):838-854. PubMed ID: 27873333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of censored exposure data by constrained maximization of the Shapiro-Wilk W statistic.
    Flynn MR
    Ann Occup Hyg; 2010 Apr; 54(3):263-71. PubMed ID: 19955326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Artefacts, biology and bias in museum collection research.
    Wehi PM; Whaanga H; Trewick SA
    Mol Ecol; 2012 Jul; 21(13):3103-9. PubMed ID: 22916347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment.
    Kuehne F; Jahn B; Conrads-Frank A; Bundo M; Arvandi M; Endel F; Popper N; Endel G; Urach C; Gyimesi M; Murray EJ; Danaei G; Gaziano TA; Pandya A; Siebert U
    J Comp Eff Res; 2019 Sep; 8(12):1013-1025. PubMed ID: 31512926
    [No Abstract]   [Full Text] [Related]  

  • 57. The design and analysis of state-trace experiments.
    Prince M; Brown S; Heathcote A
    Psychol Methods; 2012 Mar; 17(1):78-99. PubMed ID: 22040373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment.
    Schimetta W; Poelz G; Poelz W; Haring HP; Aichner F
    Arthritis Res Ther; 2004 Nov; 7(1):E2. PubMed ID: 15642128
    [No Abstract]   [Full Text] [Related]  

  • 59. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers.
    Steele R; Hudson M
    Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of censored variables on family studies.
    van den Oord EJ; Rowe DC
    Behav Genet; 1997 Mar; 27(2):99-112. PubMed ID: 9145548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.